A Phase I Study of the Pharmacokinetic Variability and Relative Bioavailability of the Phase 3 and Common Blend Formulations of Eliglustat in Healthy Adult Subjects

NCT01452542 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteer

Interventions

DRUG: Eliglustat, common blend proposed commercial formulation
DRUG: Eliglustat, Phase 3 capsule formulation

Sponsor

Genzyme, a Sanofi Company